CTEC.L Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 18:48):

Stats
Tagesvolumen	13.77M
Durchschnittsvolumen	7.44M
Marktkapitalisierung	5.26B
EPS	£0 ( 2024-03-05 )
Last Dividend	£1.380 ( 2023-08-17 )
Next Dividend	£0 ( N/A )
P/E	51.56
ATR14	£0.438 (0.17%)

Volumen Korrelation

Lang: 0.04 (neutral)

Kurz: 0.53 (weak)

Signal:(47.405) Neutral

ConvaTec Group PLC Korrelation

10 Am meisten positiv korreliert
GHT.L	0.837
DWF.L	0.827
NTOG.L	0.817
3SAP.L	0.811
MCM.L	0.809
CNIC.L	0.807
WINE.L	0.806
SBEM.L	0.805

10 Am meisten negativ korreliert
TRD.L	-0.829
BVIC.L	-0.811
B90.L	-0.809
3LAP.L	-0.808

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

ConvaTec Group PLC Korrelation - Währung/Rohstoff

0.50
( neutral )

0.20
( neutral )

0.62
( weak )

0.45
( neutral )

0.10
( neutral )

0.07
( neutral )

ConvaTec Group PLC Finanzdaten

Annual	2023
Umsatz:	£2.14B
Bruttogewinn:	£1.20B (56.04 %)
EPS:	£0.0640

FY	2023
Umsatz:	£2.14B
Bruttogewinn:	£1.20B (56.04 %)
EPS:	£0.0640

FY	2022
Umsatz:	£2.07B
Bruttogewinn:	£1.12B (53.92 %)
EPS:	£0.0311

FY	2021
Umsatz:	£2.04B
Bruttogewinn:	£1.12B (55.10 %)
EPS:	£0.0590

Financial Reports:

No articles found.

ConvaTec Group PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£1.410 (N/A)	£0 (N/A)	£0 (N/A)	£3.66 (N/A)	£1.380 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

ConvaTec Group PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.79 - good (87.87%) | Divividend Growth Potential Score: 3.50 - Decrease likely (29.98%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£1.061	2017-09-07
Last Dividend	£1.380	2023-08-17
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	13	--
Total Paid Out	£28.05	--
Avg. Dividend % Per Year	1.46%	--
Score	3.56	--
Div. Sustainability Score	8.79
Div.Growth Potential Score	3.50
Div. Directional Score	6.14	--

Next Divdend (Est)
(2024-07-09)

£1.081 Estimate 12.20 %

Dividend Stability

0.49 Below Average

Dividend Score

3.56

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2017	£0	0.00%
2018	£4.40	2.05%
2019	£4.50	3.31%
2020	£4.40	2.23%
2021	£4.08	1.99%
2022	£4.57	2.36%
2023	£5.04	2.16%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHED.L	Dividend Knight	2023-06-29	Semi-Annually	9	2.67%
IHC.L	Dividend Junior	2023-06-29	Semi-Annually	5	0.40%
BNKR.L	Dividend King	2023-07-27	Quarterly	53	1.57%
YU.L	Dividend Junior	2023-06-01	Sporadic	9	0.14%
NXT.L	Dividend Knight	2023-07-06	Annually	32	1.71%
EPIC.L	Dividend King	2023-09-14	Monthly	10	4.08%
SRP.L	Dividend Knight	2023-09-07	Annually	32	0.97%
JIM.L	Dividend King	2023-08-17	Quarterly	20	4.18%
CAM.L	Dividend Junior	2023-09-14	Annually	32	1.66%
PRV.L	Dividend Knight	2023-07-20	Semi-Annually	32	0.57%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0608	1.500	8.78	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0351	1.200	8.83	10.00	[0 - 0.3]
returnOnEquityTTM	0.0785	1.500	-0.239	-0.358	[0.1 - 1]
payoutRatioTTM	0.850	-1.000	1.504	-1.504	[0 - 1]
currentRatioTTM	1.622	0.800	6.89	5.51	[1 - 3]
quickRatioTTM	0.686	0.800	-0.669	-0.535	[0.8 - 2.5]
cashRatioTTM	0.182	1.500	-0.100	-0.150	[0.2 - 2]
debtRatioTTM	0.353	-1.500	4.11	-6.17	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.177	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.115	2.00	9.94	10.00	[0 - 20]
debtEquityRatioTTM	0.775	-1.500	6.90	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.562	1.000	3.97	3.97	[0.2 - 0.8]
operatingProfitMarginTTM	0.131	1.000	9.39	9.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.280	1.000	9.56	9.56	[0.2 - 2]
assetTurnoverTTM	0.577	0.800	9.49	7.59	[0.5 - 2]
Total Score				8.79

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	51.24	1.000	4.93	0	[1 - 100]
returnOnEquityTTM	0.0785	2.50	-0.153	-0.358	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.115	2.00	9.96	10.00	[0 - 30]
dividendYielPercentageTTM	1.520	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.177	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0.850	1.500	1.504	-1.504	[0 - 1]
pegRatioTTM	-63.57	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.171	1.000	8.21	0	[0.1 - 0.5]
Total Score				3.50

ConvaTec Group PLC

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.